Literature DB >> 13904321

Summary of current information on 6-azauridine.

R E HANDSCHUMACHER, P CALABRESI, A D WELCH, V BONO, H FALLON, E FREI.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS/pharmacology; NUCLEOSIDES AND NUCLEOTIDES/pharmacology

Mesh：

Substances：

Year:  1962        PMID： 13904321

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  7 in total

1.  THE EFFECT OF 6-AZAURIDINE ADMINISTRATION ON DE NOVO PYRIMIDINE PRODUCTION IN CHRONIC MYELOGENOUS LEUKEMIA.

Authors:  V H BONO; S M WEISSMAN; E FREI
Journal:  J Clin Invest       Date:  1964-07       Impact factor: 14.808

Review 2.  Causes and problems of nonresponse or poor response to drugs.

Authors:  P Salvà Lacombe; J A García Vicente; J Costa Pagès; P Lucio Morselli
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 3.  New indications for 6-azauridine treatment in man. A review.

Authors:  J Elis; H Rasková
Journal:  Eur J Clin Pharmacol       Date:  1972-03       Impact factor: 2.953

Review 4.  [The RNA metabolism of the mammalian cell].

Authors:  J Drews
Journal:  Klin Wochenschr       Date:  1968-05-15

5.  Antibody response in psoriatic patients treated with 6-azauridine-triacetate.

Authors:  F Perlík; J Elis; M Kubíková
Journal:  Eur J Clin Pharmacol       Date:  1973-08       Impact factor: 2.953

6.  Influence of 6-azauridine on the calcium content of plasma and bones in new-born chicks.

Authors:  J Grafnetterová; V Jedlicka; O Smahel
Journal:  Experientia       Date:  1968-11-15

7.  Hydrolysis of the prodrug, 2',3',5'-triacetyl-6-azauridine.

Authors:  C M Riley; M A Mummert; J Zhou; R L Schowen; D G Vander Velde; M D Morton; M Slavik
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.